1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>Germany

CSL Makes Landmark National-Level Pay-For-Performance Deal In Germany For Hemgenix

 
• By Francesca Bruce

A blanket pricing agreement CSL has formed with German health insurers for the gene therapy, Hemgenix, makes the cost of treatment budget-neutral compared to traditional treatment.

CSL Behring's gene therapy Hemgenix is the subject of a first-of-a-kind pay for performance deal with Germany's national insurers. (Shutterstock)
Key Takeaways
  • CSL Behring has reached a first-of-a-kind agreement with the umbrella organization for health insurers in Germany for a pay-for-performance deal.
  • The deal allows for treatment success to be measured at an individual patient level.
  • Annual payments will be budget-neutral for insurers.

CSL Behring has negotiated a first-of-a-kind pricing deal with the GKV-SV, the umbrella body representing German health insurers, for its one-time hemophilia gene therapy Hemgenix (etranacogene dezaparvovec). It says the...

Hemgenix, an orphan drug, was the first gene therapy to be approved in the EU for the treatment of severe and moderately severe hemophilia B in adults with no history...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Germany

CSL Makes Landmark National-Level Pay-For-Performance Deal In Germany For Hemgenix

 
• By Francesca Bruce

A blanket pricing agreement CSL has formed with German health insurers for the gene therapy, Hemgenix, makes the cost of treatment budget-neutral compared to traditional treatment.

German Ordinance To Implement HTA Reg Leaves Room For Doubt

 
• By Francesca Bruce

A German ordinance implementing the EU Health Technology Assessment Regulation offers little clarity on how far joint clinical assessment reports should be considered by national authorities.

German, Dutch And Italian HTA Processes Not Supportive Of RWD, Say Companies

 
• By Eliza Slawther

Payers and health technology assessment bodies in the Netherlands, Germany and Italy are either unwilling to use real-world data in assessments or cannot due to their existing frameworks, say representatives from Gilead Sciences and Autolus Therapeutics.

German Agency’s 2025 Plan Highlights EU HTA Reg, Long Covid And Smoking Cessation Drugs

 
• By Francesca Bruce

An ordinance came into effect on 8 March to ensure that joint clinical assessments can be incorporated into the German pricing and reimbursement system.

More from Health Technology Assessment

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.